MADRID, SPAIN— mAbxience, a biopharmaceutical leader partially owned by Fresenius Kabi and Insud Pharma, today announced the appointment of Jurgen Van Broeck as its new Chief Executive Officer. Van Broeck, who has effectively led the company’s commercial strategies as the Global Commercial Director since June 2023, steps into his new role with a wealth of experience in the pharmaceutical and biosimilars sectors.
Before ascending to the CEO position, Jurgen was pivotal in spearheading mAbxience’s strategic initiatives, including enhancing commercial, business development, and market access activities. His leadership was crucial in establishing strategic partnerships and advancing the company’s Contract Development and Manufacturing Organization (CDMO) services, significantly boosting mAbxience’s global stature and its commitment to providing accessible, high-quality medicines worldwide.
With nearly two decades in the healthcare industry, Jurgen’s background includes impactful tenures at multinational corporations like Merck and Mundipharma. He has been influential in launching the first immunology biosimilar in various regions, orchestrating major licensing deals, and leading commercial operations across several markets.
Upon his appointment, Jurgen expressed his vision for the company, stating, “I am honored to lead mAbxience in this exciting growth phase of the company as we continue to strive for excellence in everything we do. Our mission to provide quality, affordable biological medicines and deliver worldclass CDMO services, remain at the core of our strategy. I look forward to working closely with our talented team to advance our pipeline, expand our global footprint and become a world known CDMO for biologics.”
Under Jurgen’s leadership, mAbxience is poised to continue its trajectory as a prominent player in the global biopharmaceutical market. The company maintains a strong commitment to enhancing life quality through universal access to high-quality biopharmaceuticals, supported by a robust product pipeline and strategic international partnerships.
About mAbxience:
mAbxience is a Spanish-based biotechnology firm specializing in the development, production, and commercialization of biopharmaceuticals. In August 2022, Fresenius Kabi, part of the global healthcare organization Fresenius, acquired a majority stake in mAbxience through a strategic agreement with Insud Pharma, positioning it as a vertically integrated leader in the biotech industry. The company plays a critical role in the global healthcare sector, aiming to bridge gaps in access to affordable biological medicines.
Read Also : Imagination in a Disrupted Age: Navigating the Future with Curiosity and Empathy
